← Back to Clinical Trials
Recruiting NCT07324070

NCT07324070 Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07324070
Status Recruiting
Phase
Sponsor Charles University, Czech Republic
Condition Major Depressive Disorder (MDD)
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-01-05
Primary Completion 2028-01-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Electroconvulsive therapyTranscranial Magnetic Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-01-05 with a primary completion date of 2028-01-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The RTMSECT2 study was design to compare the application of electroconvulsive therapy augmented by transcranial magnetic stimulation. Subject will be compared both within groups and in group using psychometric scales and different deliver energy

Eligibility Criteria

Inclusion Criteria: * Age equal to 18 or higher * MADRS (Montgomery-Asberg Depression Scale) qual or higher than 20 * Major depressive disorder according to ICD 10 Exclusion Criteria: * Other axis 1 disorder (for example schizofrenia, addiction, etc.) * No dementia * ECT in the last 3 months * TMS in the last 3 months * Psychotic disease or symptoms * Ppregnancy or lactation * Any neurological disease (for example epilepsy, etc.) * Participation in another clinical trial within the last 30 days * somatic condition which contraindicates ECT

Contact & Investigator

Central Contact

Daniel Divacky

✉ daniel.divacky@lf1.cuni.cz

📞 +420 224 965 357

Frequently Asked Questions

Who can join the NCT07324070 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Major Depressive Disorder (MDD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07324070 currently recruiting?

Yes, NCT07324070 is actively recruiting participants. Contact the research team at daniel.divacky@lf1.cuni.cz for enrollment information.

Where is the NCT07324070 trial being conducted?

This trial is being conducted at Prague, Czechia.

Who is sponsoring the NCT07324070 clinical trial?

NCT07324070 is sponsored by Charles University, Czech Republic. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology